1. A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLOVIR (VG) IN SUBJECTS WITH EPSTEIN‐BARR VIRUS (EBV)‐ASSOCIATED LYMPHOMAS. (12th June 2019) Authors: Porcu, P.; Haverkos, B.; Brem, E.; Vallurupalli, A.; Feldman, T.; Alpdogan, O.; Brammer, J.; Bryan, L.J.; Barta, S.; Schriefer, A.; Obrzut, S.; Shen, H.; Rochford, R.; Baiocchi, R.; Casper, C.; Gutheil, J.; Melink, T.; Kearns, C.; Burner, D.; McRae, R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patient-informed learning to assist development of personalised treatment care plans for breast cancer patients and survivors. (October 2020) Authors: Kearns, C.; Burke, A.; Gallagher, W.M.; Kelly, C.M. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The Lancet Oral Health Series: Implications for Oral and Dental Research. (January 2020) Authors: Watt, R.G.; Daly, B.; Allison, P.; Macpherson, L.M.D.; Venturelli, R.; Listl, S.; Weyant, R.J.; Mathur, M.R.; Guarnizo-Herreño, C.C.; Celeste, R.K.; Peres, M.A.; Kearns, C.; Benzian, H. Journal: Journal of dental research Issue: Volume 99:Number 1(2020) Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗